Stay updated on Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedRevision: v3.3.3 has been added to the page footer, and HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page history shows a new Revision: v3.3.2 replacing v3.3.1. No substantive changes to the study record or visible content are shown.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.1 on the page footer.SummaryDifference0.0%

- Check67 days agoChange DetectedThe funding/operating status notice was removed from the page; the rest of the record history and trial details remain unchanged.SummaryDifference0.3%

- Check81 days agoChange DetectedThe Record History page displays a redesigned layout and updated styling for the version list, while the underlying version data remains unchanged.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page.